Unknown

Dataset Information

0

Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8+ T Cells, Regulatory T Cells, and Myeloid-Derived Suppressor Cells in Soft Tissue Sarcoma.


ABSTRACT: Soft tissue sarcoma (STS) is a rare solid malignant cancer, and there are few effective treatment options for advanced disease. Cancer immunotherapy is a promising new strategy for STS treatment. IL-33 is a candidate cytokine for immunotherapy that can activate T lymphocytes and modulate antitumor immunity in some cancers. However, the expression and biological role of IL-33 in STS are poorly understood. In this study, we found that the expression of IL-33 and its receptor ST2 was decreased in STS using real-time PCR assays. By analyzing sarcoma data from The Cancer Genome Atlas, we found that higher transcriptional levels of IL-33 and ST2 were associated with a favorable outcome. There were positive correlations between the expression levels of ST2 and CD3E, CD4, CD8A, CD45RO, FOXP3, CD11B, CD33, and IFN-?. Strong positive correlations between the expression of IFN-? and CD3E and CD8A were also observed. Moreover, the expression levels of both IL-33 and ST2 were positively correlated with those of CD3E, CD8A, and chemokines that recruit CD8+ T cells, indicating that the IL-33/ST2 axis may play an important role in recruiting and promoting the immune response of type 1-polarized CD8+ T cells in STS. Meanwhile, we also found that the expression of IL-33 was negatively correlated with that of TGF-?1 and chemokines that recruit regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), indicating that the IL-33/ST2 axis may also contribute to antagonizing Tregs, MDSCs, and TGF-?1-mediated immunosuppression in STS. The correlations between the IL-33/ST2 axis and CD8+ T cells and IFN-?, as well as Tregs, MDSCs, and TGF-?1 were validated by additional analyses using three other independent GEO datasets of sarcoma. Our results implicate the possible role of the IL-33/ST2 axis in modulating antitumor immunity in STS. IL-33 may not only serve as a useful prognostic biomarker for STS but also as a potential therapeutic target for STS immunotherapy and worth further investigation.

SUBMITTER: Chen H 

PROVIDER: S-EPMC5986931 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8<sup>+</sup> T Cells, Regulatory T Cells, and Myeloid-Derived Suppressor Cells in Soft Tissue Sarcoma.

Chen Huoying H   Chen Yao Y   Liu Hongbo H   Que Yi Y   Zhang Xing X   Zheng Fang F  

Frontiers in immunology 20180529


Soft tissue sarcoma (STS) is a rare solid malignant cancer, and there are few effective treatment options for advanced disease. Cancer immunotherapy is a promising new strategy for STS treatment. IL-33 is a candidate cytokine for immunotherapy that can activate T lymphocytes and modulate antitumor immunity in some cancers. However, the expression and biological role of IL-33 in STS are poorly understood. In this study, we found that the expression of IL-33 and its receptor ST2 was decreased in S  ...[more]

Similar Datasets

| S-EPMC10017706 | biostudies-literature
| 2381881 | ecrin-mdr-crc
| S-EPMC7519271 | biostudies-literature
| S-EPMC8105666 | biostudies-literature
| S-EPMC10700222 | biostudies-literature
| S-EPMC6185962 | biostudies-literature
| S-EPMC9112898 | biostudies-literature
| S-EPMC10667825 | biostudies-literature
| S-EPMC7430493 | biostudies-literature
| S-EPMC10310784 | biostudies-literature